Is Halozyme Therapeutics, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Halozyme Therapeutics, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 14, an EV to EBITDA of 10.96, and a PEG ratio of 0.22, which suggests strong growth potential relative to its price.
In comparison to peers, Halozyme's P/E ratio is lower than Illumina, Inc. at 19.09 and BioMarin Pharmaceutical, Inc. at 15.17, indicating it may be more attractively priced within its industry. Notably, Halozyme has a high ROE of 100.64% and ROCE of 48.11%, showcasing its efficient use of capital. Over the past year, Halozyme has returned 28.21%, outperforming the S&P 500's return of 14.08%, reinforcing its favorable valuation narrative.